Erratum: Aktuelle und zukünftige pharmakologische Therapieoptionen zur Behandlung der Osteoporose und deren Wirkmechanismen – ein Überblick

Erratum

Aktuelle und zukünftige pharmakologische Therapieoptionen zur Behandlung der Osteoporose und deren Wirkmechanismen – ein Überblick

Fößl I, Obermayer-Pietsch B. Osteologie 2024; 33: 67–73.

DOI: 10.1055/a-2304-7012

Im oben genannten Artikel ist die Tab. 1 fehlerhaft. Die korrekte Tabelle ist unten abgebildet.

Tab. 1 Pharmakologische Behandlungsmöglichkeiten bei Osteoporose und deren präventiver Effekt auf verschiedene Frakturen mit den relevantesten Sicherheitsaspekten und Zulassungsmodalitäten, modifiziert nach [60]
Table 1 Pharmacological treatment options for osteoporosis and their preventive effect on different types of fractures, including relevant safety aspects and approvals, modified from [60].

Substanz	Dosierung	Applikation	Effekt auf vertebrale Frakturen	Effekt auf non-vertebrale Frakturen	Effekt auf Frakturen der Hüfte	Relevanteste Sicherheits-aspekte	Zulassung für	Referenzen
Alendronata	10mg täglich; 70mg wöchentlich	Oral	+	+	+	Reizungen der Magenschleimhaut, Anstieg von Kreatinin, MRONJ, AFF	Frauen und Männer; GIOP	[64] [65] [66] [67]
Risedronata	5mg täglich; 35mg wöchentlich	Oral	+	+	+		Frauen und Männer	[68] [69] [70] [71]
Ibandronatb	3mg alle 3 Monate intravenös oder 150mg einmal monatlich oral	Intravenös oder oral	+	+	-		Frauen	[72] [73] [74] [75]
Zoledronat	5mg	Intravenös	+	+	+		Frauen und Männer; GIOP; Morbus Paget	[76] [77]
Raloxifen	60 mg	Oral	+	+ c	-	Hitzewallungen, tiefe Venenthrombosen, Lungenembolien, Netzhautvenenthrombosen	Frauen	[78] [79] [80]
Bazedoxifen	20 mg	Oral	+	+ / - d	-		Frauen	[16, 81] [82] [83] [84]
Teriparatid	20 µg täglich für max 2 years	Subkutan	+	+	-	Hyperkalzämie, Hyperkalziurie, Hyperurikämie, Osteosarkom, orthostatische Hypotension	Frauen und Männer; GIOP	[21, 85]
Abaloparatid	80 µg täglich bei maximal totaler Verabreichungsdauer von 18 Monaten	Subkutan	+	+	+		In der EU zugelassen für Frauen; in den USA zugelassen für Frauen und Männer	[86] [87] [88] [89]
Denosumab	60mg alle 6 Monate	Subkutan	+	+	+	Hypokalzämie, Wirbelfrakturen, MRONJ, AFF, Nierenschädigung, Hautinfektionen	Frauen und Männer, MHA, GIOP	[90] [91]
Romosozumab	210mg monatlich für 1 Jahr	Subkutan	+	+	+	Kardiovaskuläre (im Vergleich mit Alendronat)	Frauen	[92] [93]
MHT / HRTf	Abhängig vom Therapieziel	Abhängig von Substanz und Indikation	+	+	+	Venöse Thromboembolien, Lungenembolien, Brustkrebs	NA	[94] [95] [96] [97] [98] [99] [100] [101]

+ Die Substanz zeigt eine Wirkung auf die jeweilige Fraktur; - die Substanz zeigt keine bekannte Wirkung auf die jeweilige Fraktur; ± die Substanz zeigt kontroverse Studienergebnisse in Bezug auf die jeweilige Fraktur. AFF, atypische Femurfraktur; EU, Europäische Union; GIOP, Glukokortikoid-induzierte Osteoporose; HRT, Hormonersatztherapie; MHA, Knochenverlust in Verbindung mit Hormonablation bei Männern mit Prostatakrebs und erhöhtem Frakturrisiko; MHT, postmenopausale Hormontherapie; MRONJ, medikamentenbedingte Osteonekrose des Kiefers. ^aKeine direkten Belege für die frakturhemmende Wirksamkeit bei einmal wöchentlicher Verabreichung. ^bKeine direkten Belege für die frakturhemmende Wirksamkeit bei vierteljährlicher intravenöser Verabreichung von 3 mg. ^cBei PatientInnen mit vorbestehender schwerer Wirbelfraktur. ^dKontroverse Ergebnisse.. fFrakturinzidenz kein primärer Endpunkt.

Publication History

Article published online:
26 July 2024

• 64 Liberman UA, Weiss SR, Bröll J. et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333: 1437-1444
• 65 Schnitzer T, Bone HG, Crepaldi G. et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging Clin Exp Res 2000; 12: 1-12
• 66 Black DM, Cummings SR, Karpf DB. et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535-1541
• 67 Axelsson KF, Wallander M, Johansson H. et al. Hip fracture risk and safety with alendronate treatment in the oldest-old. J Intern Med 2017; 282: 546-559
• 68 McClung MR, Balske A, Burgio DE. et al. Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years. Osteoporos Int 2013; 24: 301-310
• 69 McClung MR, Geusens P, Miller PD. et al. Effect of Risedronate on the Risk of Hip Fracture in Elderly Women. N Engl J Med 2001; 344: 333-340
• 70 Reginster JY, Minne HW, Sorensen OH. et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000; 11: 83-91
• 71 Harris ST, Watts NB, Genant HK. et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282: 1344-1352
• 72 Miller PD, Recker RR, Harris S. et al. Long-term fracture rates seen with continued ibandronate treatment: Pooled analysis of DIVA and MOBILE long-term extension studies. Osteoporos Int 2014; 25: 349-357
• 73 Harris ST, Blumentals WA, Miller PD. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: Results of a meta-analysis of phase III studies. In: Current Medical Research and Opinion. Taylor & Francis; 2008: 237-245
• 74 Delmas PD, Recker RR, Chesnut CH. et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004; 15: 792-798
• 75 Chesnut CH, Skag A, Christiansen C. et al. Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis. J Bone Miner Res 2004; 19: 1241-1249
• 76 Black DM, Delmas PD, Eastell R. et al. Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. N Engl J Med 2007; 356: 1809-1822
• 77 Lyles KW, Colón-Emeric CS, Magaziner JS. et al. Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture. N Engl J Med 2007; 357: 1799-1809
• 78 Recker RR, Kendler D, Recknor CP. et al. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. Bone 2007; 40: 843-851
• 79 Delmas PD, Genant HK, Crans GG. et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: Results from the MORE trial. Bone 2003; 33: 522-532
• 80 Ettinger B, Black DM, Mitlak BH. et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282: 637-645
• 81 Ellis AG, Reginster JY, Luo X. et al. Indirect comparison of bazedoxifene vs oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic women. Curr Med Res Opin 2014; 30: 1617-1626
• 82 Ellis AG, Reginster JY, Luo X. et al. Bazedoxifene versus oral bisphosphonates for the prevention of nonvertebral fractures in postmenopausal women with osteoporosis at higher risk of fracture: a network meta-analysis. Value Health 2014; 17: 424-432
• 83 De Villiers TJ, Chines AA, Palacios S. et al. Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporos Int 2011; 22: 567-576
• 84 Kanis JA, Johansson H, Oden A. et al. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 2009; 44: 1049-1054
• 85 Kendler DL, Marin F, Zerbini CAF. et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2018; 391: 230-240
• 86 Reginster JY, Bianic F, Campbell R. et al. Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis. Osteoporos Int 2019; 30: 1465-1473
• 87 McCloskey EV, Fitzpatrick LA, Hu MY. et al. Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability. Arch Osteoporos 2019; 14
• 88 Miller PD, Hattersley G, Riis BJ. et al. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. JAMA 2016; 316: 722-733
• 89 Cosman F, Cooper C, Wang Y. et al. Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: A US administrative claims database study. Osteoporos Int 2022; 33: 1703-1714
• 90 Cummings SR, Martin JS, McClung MR. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756-765
• 91 Broadwell A, Chines A, Ebeling PR. et al. Denosumab Safety and Efficacy Among Participants in the FREEDOM Extension Study With Mild to Moderate Chronic Kidney Disease. J Clin Endocrinol Metab 2021; 106: 397-409
• 92 Geusens P, Oates M, Miyauchi A. et al. The Effect of 1 Year of Romosozumab on the Incidence of Clinical Vertebral Fractures in Postmenopausal Women With Osteoporosis: Results From the FRAME Study. JBMR Plus 2019; 3
• 93 Saag KG, Petersen J, Brandi ML. et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med 2017; 377: 1417-1427
• 94 Zhu L, Jiang X, Sun Y. et al. Effect of hormone therapy on the risk of bone fractures: A systematic review and meta-analysis of randomized controlled trials. Menopause 2016; 23: 461-470
• 95 Bagger YZ, Tankó LB, Alexandersen P. et al. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone 2004; 34: 728-735
• 96 Banks E, Beral V, Reeves G. et al. Fracture Incidence in Relation to the Pattern of Use of Hormone Therapy in Postmenopausal Women. JAMA 2004; 291: 2212-2220
• 97 Anderson GL, Limacher M, Assaf AR. et al. Effects of Conjugated Equine Estrogen in Postmenopausal Women with Hysterectomy: The Women’s Health Initiative Randomized Controlled Trial. JAMA 2004; 291: 1701-1712
• 98 Rossouw JE, Anderson GL, Prentice RL. et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333
• 99 Hadji P, Ryan KA, Yu CR. et al. CE/BZA effects on bone and quality of life in European postmenopausal women: a pooled analysis. Climacteric 2016; 19: 482-487
• 100 Cauley JA, Robbins J, Chen Z. et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA 2003; 290: 1729-1738
• 101 Torgerson DJ, Bell-Syer SEM. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 2001; 285: 2891-2897